CJ Bioscience, Inc. (KOSDAQ:311690)
South Korea · Delayed Price · Currency is KRW 4,610.00
-190.00 (-3.96%)
At close: Jun 19, 2026
CJ Bioscience Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | - | 3,693 | 3,467 | 5,575 | 4,075 | 4,363 |
Other Revenue | -0 | -0 | - | -0 | - | - |
| 3,563 | 3,693 | 3,467 | 5,575 | 4,075 | 4,363 | |
Revenue Growth (YoY) | 5.56% | 6.52% | -37.82% | 36.82% | -6.61% | -17.86% |
Cost of Revenue | 2,971 | 3,060 | 3,182 | 3,802 | 2,763 | 2,721 |
Gross Profit | 591.65 | 632.96 | 284.83 | 1,773 | 1,311 | 1,642 |
Selling, General & Admin | 5,810 | 5,930 | 9,668 | 9,371 | 12,970 | 5,934 |
Research & Development | 16,904 | 18,051 | 23,167 | 22,823 | 19,186 | 4,852 |
Amortization of Goodwill & Intangibles | 13.77 | 14.06 | 15.38 | 17.24 | 33.18 | 29.06 |
Other Operating Expenses | 171.17 | 189.74 | 221.72 | 203.41 | 111.59 | 77.13 |
Operating Expenses | 24,123 | 25,419 | 34,526 | 33,829 | 34,545 | 11,750 |
Operating Income | -23,531 | -24,786 | -34,241 | -32,057 | -33,233 | -10,108 |
Interest Expense | -564.9 | -540.18 | -587.41 | -922.05 | -2,763 | -4,968 |
Interest & Investment Income | 1,706 | 1,935 | 1,913 | 1,367 | 1,331 | 410.15 |
Earnings From Equity Investments | - | - | - | 75.66 | - | - |
Currency Exchange Gain (Loss) | 17.95 | 15.04 | -68.27 | -39.39 | 12.64 | 2.91 |
Other Non Operating Income (Expenses) | 7.45 | 9.99 | 134.84 | 19.86 | 129.82 | -2,485 |
EBT Excluding Unusual Items | -22,364 | -23,366 | -32,849 | -31,555 | -34,523 | -17,148 |
Gain (Loss) on Sale of Assets | -639.62 | -638.74 | 10.89 | 8,642 | -390.7 | 10.43 |
Asset Writedown | - | - | - | - | - | -170.67 |
Other Unusual Items | - | - | - | - | - | -1,964 |
Pretax Income | -23,004 | -24,005 | -32,838 | -22,913 | -34,913 | -19,272 |
Net Income | -23,004 | -24,005 | -32,838 | -22,913 | -34,913 | -19,272 |
Net Income to Common | -23,004 | -24,005 | -32,838 | -22,913 | -34,913 | -19,272 |
Shares Outstanding (Basic) | 13 | 13 | 9 | 7 | 6 | 4 |
Shares Outstanding (Diluted) | 13 | 13 | 9 | 7 | 6 | 4 |
Shares Change (YoY) | 27.31% | 40.89% | 30.92% | 20.52% | 38.23% | 10.14% |
EPS (Basic) | -1760.74 | -1837.29 | -3541.00 | -3234.63 | -5940.02 | -4532.31 |
EPS (Diluted) | -1760.74 | -1837.29 | -3541.00 | -3235.00 | -5940.02 | -4533.00 |
Free Cash Flow | -19,846 | -23,427 | -28,138 | -29,823 | -25,108 | -9,390 |
Free Cash Flow Per Share | -1519.06 | -1793.05 | -3034.18 | -4210.07 | -4271.74 | -2208.24 |
Gross Margin | 16.61% | 17.14% | 8.22% | 31.80% | 32.19% | 37.62% |
Operating Margin | -660.47% | -671.24% | -987.76% | -575.00% | -815.61% | -231.68% |
Profit Margin | -645.68% | -650.10% | -947.28% | -410.99% | -856.84% | -441.72% |
Free Cash Flow Margin | -557.05% | -634.44% | -811.70% | -534.93% | -616.19% | -215.22% |
EBITDA | -19,636 | -20,773 | -29,920 | -26,911 | -29,333 | -8,546 |
EBITDA Margin | - | - | - | - | - | -195.88% |
D&A For EBITDA | 3,895 | 4,013 | 4,321 | 5,146 | 3,900 | 1,562 |
EBIT | -23,531 | -24,786 | -34,241 | -32,057 | -33,233 | -10,108 |
EBIT Margin | - | - | - | - | - | -231.67% |
Advertising Expenses | - | 127.07 | 123.79 | 160.85 | 131.39 | 58.02 |